Researchers and drug developers need reliable information on protein expression throughout the body. This webinar will focus on the subcellular mapping of the human proteome within The Human Protein Atlas project and how to make use of the data from the open access Human Protein Atlas database (www.proteinatlas.org). Given the antibody-centric approach of this project, the antibody specificity and validation is crucial to obtain reliable data. The webinar will also address antibody validation for different applications, based on the recommendations from The Human Protein Atlas project as part of the International Working Group on Antibody Validation (IWGAV).
Antibodies are versatile tools for studying the human proteome and in combination with imaging applications, specific proteins can be visualized within tissues, cells and subcellular organelles. The Human Protein Atlas project aims to create an atlas of the human proteome, using antibodies and microscopy to gain spatial protein distribution in tissues, cells and at the subcellular level. Three main publications, all in the journal Science, describe and summarize the work and conclusions of the respective sub atlases (Uhlen et al 2015 and 2017, Thul et al 2017).
Resolving the spatial distribution of the human proteome at a subcellular level greatly increases our understanding of human biology and disease. Using antibodies generated within the Human Protein Atlas project, immunofluorescence and confocal microscopy were applied to systematically explore the spatial distribution of over 12,000 human proteins in cultivated cell lines and map them to 30 subcellular structures with single-cell resolution. From this extensive subcellular protein profiling data, 13 different organelle proteomes could be defined. Exploration of the proteomes reveals single-cell variations of abundance or spatial distribution and localization of approximately half of the proteins to multiple compartments. This subcellular map can be used to refine existing protein-protein interaction networks and provides an important resource to deconvolute the highly complex architecture of the human cell.
The Human Protein Atlas project has, in many senses, been part of a world-leading effort in improving antibody validation standards. The experience from using over 40,000 in-house generated antibodies as well as commercial antibodies from different vendors, has led to the conclusions of context-dependent antibodies and thus the need for application-specific validation methods, as described by IWGAV.
To conclude, the Protein Atlas serves as a protein information resource, where expression profiles in over forty different tissues and several different cell types can be explored.
Charlotte Stadler, PhD, Head of Cell Profiling Facility, KTH Royal Institute of Technology, Sweden
Charlotte Stadler is a researcher at the Department of Protein Science, KTH Royal Institute of Technology. She is Head of the Cell Profiling facility, located at the Science for Life Laboratory and a researcher within of the Human Protein Atlas (HPA) project. Her research, as well as the expertise of the facility, is focused on antibody-based imaging as a way to assess spatial information of the human proteome at the cellular and subcellular level. She received her PhD after establishing the systematic pipelines that are the basis of all this work, with Prof. Emma Lundberg and Prof. Mathias Uhlén as her supervisors. She is also devoted to antibody validation and has developed many of the validation schemes used in the HPA for obtaining reliable data on subcellular protein profiling, including a high throughput platform for siRNA mediated knock-down and workflows for recombinant expression validation using GFP-tagging.Message Presenter
Who Should Attend?
This webinar will be ideal for academic and pharmaceutical researchers, including those who are:
- Interested in using an antibody-based approach for basic research and drug discovery
- Looking for an open-access resource for proteome information
What You Will Learn
- How to make use of the data from the open access Human Protein Atlas database (www.proteinatlas.org)
- Recommendations for application-specific antibody validation, as part of the International Working Group on Antibody Validation (IWGAV)
Horizon Discovery Group
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.
Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.